Abstract
Patients with relapsed small cell lung cancer (SCLC) have limited treatment options and dismal survival. Phase II study shows the moderate activity of anlotinib monotherapy (a novel multitarget tyrosine kinase angiogenesis inhibitor) in previously treated SCLC. The purpose of this study is to assess the efficacy and safety of anlotinib combination with oral fluoropyrimidine S1 in patients with Refractory or Relapsed SCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
